Ovarian cancer staging: Does it require a gynecologic oncologist?

Allan R. Mayer, Setsuko K. Chambers, Ellen Graves, Carole Holm, Paul C. Tseng, Beth E. Nelson, Peter E. Schwartz

Research output: Contribution to journalArticle

126 Scopus citations

Abstract

Forty-seven patients with presumed Stages I-II invasive ovarian epithelial carcinoma were treated with intravenous 50 mg/m2cis-platinum, for 2-18 cycles (median, 9), 50 mg/m2 doxorubicin for 2-14 cycles (median, 9), and/or 600 mg/m2 cyclophosphamide for 2-14 cycles (median, 6) after surgical staging by a gynecologic oncologist or a nononcologic surgeon. Mean follow-up is 6.8 years. Cumulative 5-year actuarial survival is 73 ± 6%; 75 ± 12% for Stage I and 71 ± 8% for Stage II disease. When screened for poor prognosticators, only the specialty of the operating surgeon was identified (P < 0.05). Five-year actuarial survival and disease-free survival, respectively, for Stages I-II patients surgically staged by a gynecologic oncologist were 83 ± 7% and 76 ± 8%, compared to 59 ± 11% (P < 0.05) and 39 ± 11% (P < 0.03) for the group operated upon by a nononcologist.

Original languageEnglish (US)
Pages (from-to)223-227
Number of pages5
JournalGynecologic oncology
Volume47
Issue number2
DOIs
StatePublished - Nov 1992
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Ovarian cancer staging: Does it require a gynecologic oncologist?'. Together they form a unique fingerprint.

  • Cite this

    Mayer, A. R., Chambers, S. K., Graves, E., Holm, C., Tseng, P. C., Nelson, B. E., & Schwartz, P. E. (1992). Ovarian cancer staging: Does it require a gynecologic oncologist? Gynecologic oncology, 47(2), 223-227. https://doi.org/10.1016/0090-8258(92)90110-5